The Street Insider 7/30/13
Needham & Company Maintains Bullish View on Vertex (VRTX) Following Q2 Earnings
Needham & Company analyst Alan Carr reiterate a Buy rating and $95 price target on Vertex (NASDAQ: VRTX) following Q2 results.
Dr. Alan Carr is a good biotech analyst, but he has been in a more conservative side in targeting share prices. In his earlier call he stated that his target price had not taken into account the value of VX-135. When the FDA removes the clinical hold on the 200 mg dosing resimen of VX-135, his target price should jump to $125.
Regarding the clinical hold on the 200 mg of 135 in the US, does that mean that the 200 mg group, some of whom may have only take 6 weeks of of 135, had to stop taking it ? If so wouldn't that cause harm such as mutation of the virus? Is it possible that those who had not completed the 200 mg regimen were switched to 100 mg for the remainder of their scheduled treatment?